<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174668</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_3504</org_study_id>
    <secondary_id>EUDRACT # : 2004-001287-49</secondary_id>
    <nct_id>NCT00174668</nct_id>
  </id_info>
  <brief_title>Insulin Glulisine in Diabetes Mellitus, Type 2</brief_title>
  <acronym>GINGER</acronym>
  <official_title>52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      The primary study objective is to demonstrate superior efficacy of an intensified insulin&#xD;
      regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin&#xD;
      regimen in terms of change in glycated hemoglobin A1c (HbA1c), from baseline to endpoint.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Secondary study objectives are to compare the intensified insulin regimen with insulin&#xD;
      glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of&#xD;
      blood glucose (BG) values (fasting, pre-/postprandial (ppBG), nocturnal, mean daily, fasting&#xD;
      plasma glucose), daily BG profiles, BG and HbA1c response rates (predefined), hypoglycemic&#xD;
      events, adverse events, change of late diabetes complications, weight, body-mass-index,&#xD;
      course of total daily insulin dose and adjustment, blood lipid profile, microalbuminuria,&#xD;
      standard lab and quality of life/treatment satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>From baseline to study endpoint</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Self monitored BG (SMBG) values</measure>
    <time_frame>During the whole treatment phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight/body mass index (BMI)</measure>
    <time_frame>From baseline to study endpoint and all other visits</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting blood lipid profile</measure>
    <time_frame>From baseline to study endpoint and all other visits</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine albumin</measure>
    <time_frame>From baseline to study endpoint and all other visits</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total daily insulin dose</measure>
    <time_frame>From baseline to study endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Throughout the study,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard laboratory tests</measure>
    <time_frame>From baseline to study endpoint and all other visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From baseline to study endpoint and all other visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>From baseline to study endpoint and all other visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two daily injection conventional insulin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Therapy</intervention_name>
    <description>NPH (70%) plus regular insulin or insulin aspart (30%)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        Subjects meeting all of the following criteria will be considered for enrollment into the&#xD;
        study:&#xD;
&#xD;
          -  Type 2 diabetes mellitus, as defined by the American Diabetes Association for at least&#xD;
             five years, treated with insulin for at least 6 months (no history of ketoacidosis).&#xD;
&#xD;
          -  HbA1c between 7.5% and 11.0%, inclusive at both pre-screening and pre-randomization&#xD;
             (week -2).&#xD;
&#xD;
          -  For at least 3 months prior to week -8 visit, subjects must have been on a stable&#xD;
             insulin regimen with two daily s.c. injections of premixed insulin: NPH plus regular&#xD;
             insulin or NPH plus rapid acting insulin (insulin lispro or insulin aspart) in a&#xD;
             mixture of 70/30 or 75/25. &quot;Stable&quot; means no change in regimen and no more than 30 %&#xD;
             change in dose. Optionally, the subject can have been treated in addition with&#xD;
             metformin according to its current official product information leaflet, treatment&#xD;
             with other oral blood glucose lowering drugs is not allowed.&#xD;
&#xD;
          -  Documentation of a full ophthalmologic exam (incl. fundoscopy)during the 6 months&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Women are either not of childbearing potential (surgically sterile, or postmenopausal&#xD;
             for more than 2 years). Women of childbearing potential must not be pregnant and agree&#xD;
             to use a reliable contraceptive measure for the duration of the study. Reliable&#xD;
             contraceptive measures include the following: systemic contraceptive (oral, implant,&#xD;
             injections), diaphragm with intravaginal spermicide, cervical cap, intrauterine device&#xD;
             or condom with spermicide.&#xD;
&#xD;
          -  Willing and able to perform specified home blood glucose monitoring and to otherwise&#xD;
             comply with study protocol requirements.&#xD;
&#xD;
          -  Willing to change from a twice daily insulin regimen to a regimen requiring four daily&#xD;
             insulin injections.&#xD;
&#xD;
          -  Provision of signed and dated informed consent prior to any study&#xD;
             procedures.&quot;Prescreening&quot; informed consent, obtained in writing for all subjects, may&#xD;
             be used during screening, but full study-specific informed consent must be obtained in&#xD;
             writing for all subjects after any post-screening procedures.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
        Subjects presenting with any of the following will not be included in the study:&#xD;
&#xD;
          -  Two or more severe hypoglycemic episodes within the past 3 months, or any&#xD;
             hospitalization or emergency room visit due to poor diabetic control within the past 3&#xD;
             months prior to randomization.&#xD;
&#xD;
          -  History of hypoglycemia unawareness.&#xD;
&#xD;
          -  Impaired hepatic function, as shown by, but not limited to, ALAT (SGPT) or ASAT (SGOT)&#xD;
             above 2x the upper limit of normal as measured at visit 1.&#xD;
&#xD;
          -  Impaired renal function, as shown by, but not limited to, serum creatinine &gt; 177&#xD;
             mmol/l (&gt; 2 mg/dl) as measured at visit 1 (if no lower values due to individual&#xD;
             metformin intake are required) or current renal dialysis.&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 38 kg/m2.&#xD;
&#xD;
          -  Any other clinically significant abnormalities on screening laboratory evaluation&#xD;
             (unless discussed with the monitor and approved by the study management).&#xD;
&#xD;
          -  Active proliferative diabetic retinopathy, as defined by the application of focal or&#xD;
             panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any&#xD;
             other unstable (rapidly progressing) retinopathy that may require surgical treatment&#xD;
             (including laser photocoagulation) during the study.&#xD;
&#xD;
          -  History of hypersensitivity to insulin or insulin analogues or any of the excipients&#xD;
             in the HMR 1964 formulation.&#xD;
&#xD;
          -  Donation of blood or transfusion during the 2 months prior to the screening visit.&#xD;
&#xD;
          -  Pregnant or lactating women, or women planning to become pregnant during the study.&#xD;
&#xD;
          -  Treatment with any investigational drug in the last month before visit 1 (screening).&#xD;
&#xD;
          -  Mental condition rendering the patient unable to understand the nature, scope, and&#xD;
             possible consequences of the study.&#xD;
&#xD;
          -  Any clinically significant major organ system disease such as relevant cardiovascular,&#xD;
             gastrointestinal, hepatic, neurologic, endocrine, hematologic or other major systemic&#xD;
             diseases making implementation of the protocol or interpretation of the study results&#xD;
             difficult.&#xD;
&#xD;
          -  Treatment or likelihood of requiring treatment during the study period with drugs not&#xD;
             permitted by the clinical study protocol.&#xD;
&#xD;
          -  History of drug or alcohol abuse within the last 2 years or current addiction to&#xD;
             substances of abuse.&#xD;
&#xD;
          -  Night shift workers.&#xD;
&#xD;
          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study.&#xD;
&#xD;
          -  Subject is the investigator or any subinvestigator, research assistant, pharmacist,&#xD;
             study coordinator, other staff or relative thereof directly involved in the conduct of&#xD;
             the protocol.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Val√©rie Pilorget, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Meyrin</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

